MedPath

Study of the improvement effect of proton pump inhibitors on symptoms in patients with reflux esophagitis (RE): a randomized double-blind comparative study of esomeprazole 20mg vs. rabeprazole 10mg

Not Applicable
Conditions
Reflux esophagitis
Registration Number
JPRN-UMIN000010450
Lead Sponsor
Juntendo University School of Medicine, Department of Gastroenterology and Hepatology
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
200
Inclusion Criteria

Not provided

Exclusion Criteria

(1)Patients with a history of gastrointestinal resection or vagotomy (2) Patients with warning signs such as vomiting, gastrointestinal bleeding (including findings of hematemesis, melena, and anemia), and sudden weight loss (3) Patients with peptic ulcer (except those in scarring stage) (4) Patients with a history of, or who currently have, any of the following diseases: - Zollinger-Ellison syndrome - Inflammatory Bowel Disease (IBD) - Irritable Bowel Syndrome (IBS) - Esophageal stricture - Esophageal achalasia - Malabsorption - Cerebrovascular disorders such as cerebral hemorrhage and cerebral infarction (5) Patients whose participation in this study would be contraindicated due to complications such as serious hepatic disease, renal disease, or cardiac disease. (6) Patients with a confirmed, or suspected, malignant lesion (7) Women who are pregnant or who may possibly be pregnant, and lactating mothers (8) Patients under atazanavir sulfate administration (9) Patients receiving treatment with proton pump inhibitors, H2-receptor antagonists, prokinetic agents, gastric mucosa protective agents, anticholinergics, antidepressants, antianxiety agents, steroids (excluding external preparations), non-steroid anti-inflammatory drugs (NSAIDs), aspirin preparations including low-dose aspirin,anticoagulant drugs and bisphosphonate drugs in the past 2 week prior to treatment. (10) Other patients whom the investigator considers unsuitable for admission to the study

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath